Corcept Therapeutics Inc (CORT)
62.49
-0.41
(-0.65%)
USD |
NASDAQ |
Apr 22, 13:40
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.593B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 174.1% |
| Valuation | |
| PE Ratio | 50.40 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.51 |
| Price to Book Value | 9.701 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.86% |
Profile
Edit
| Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
| URL | https://www.corcept.com |
| Investor Relations URL | https://ir.corcept.com/investor-relations |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 01, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
| URL | https://www.corcept.com |
| Investor Relations URL | https://ir.corcept.com/investor-relations |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 01, 2025 (est.) |
| Last Earnings Release | Feb. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |